HISTORY
May. 2020
- Changed company name to OQP Pharmaceuticals Inc. from Dual Industrial Co., Ltd Co
- Appointed Dr. Madi Madiyalakan, Dr. Jonathan S. Berek, Mr. Mark Lievonen, Dr. Michael Hollowingsworth and 4 other board members.
Apr. 2020
- Signed an asset to sign an asset transfer agreement with OQP Inc. (Canada) : Assets including Intellectual property rights, FDA clinical trial sponsorship, patent, and research assets related to immuno-cancer treatment on ovarian cancer, breast cancer, and pancreatic cancer.
Mar. 2019
- Chang Hyun Lee, became CEO of the company.
Nov. 2018
- Acquired Dual Moolsan Co., Ltd. as subsidiary
Oct. 2005
- Listed on KOSDAQ
Aug. 1993
- Establishment of Dual Industrial Co., Ltd.